Resources

Resources

{site_title}

Therapy

The thromboxane A2 pathway plays a major role in governing the reactions involved in both the inflammatory and hemostatic biological mechanisms. Cyclooxygenases 1 & 2 act to convert arachidonic acid to thromboxane A2. Scientific studies report cyclooxygenase-2 is up-regulated in many different chronic disease states as well as in chronic inflammation. This explains one major causes of residual thromboxane risk, “aspirin resistance.” Levels of urinary 11-dehydrothromboxane B2 reflect activity of components of the thromboxane A2 pathway that result n thromboxane A2 generation. The assay is normalized to the patient’s urine creatinine concentration and is non-invasive and normalized utilizing standard controls.

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stoke, or cardiovascular death in patients at high risk for cardiovascular events

"Among aspirin-treated patients at high risk of cardiovascular events, persistent thromboxane generation predicts the risk of the composite outcome of myocardial infarction, stroke, or cardiovascular death, independent of other cardiovascular risk factors."

Read More

Targeting arachidonic pathway by natural products for cancer prevention and therapy

Arachidonic acid (AA) pathway, a metabolic process, plays a key role in carcinogensis.  Hence, AA pathway metabolic enzymes phospholipase A2s (PLA2S), cyclooxygenases (COXs) and lipoxygenases (LOXs) and their metabolic products, such as prostaglandins and leukotrienes, have been considered novel preventive and therapeutic targets in cancer."

"Curcumin, resveratrol, apigenin, anthocyans, berberine, ellagic acid, eugenol, fisetin, ursolic acid, [6]-gingerol, guggulsteone, lycopene and genistein are well known cancer chemopreventive agents which act by targeting multiple pathways, including COX-2."

Read More

Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy.

"Fish oil supplementation (FOS) is known to have cardiovascular benefits.  However, the effects of FOS on thrombosis are incompletely understood.  We sought to determine if the use of FOS is associated with lower indices of atherothrombotic risk in patients with suspected coronary artery disease."

"Fish oil supplementation (FOS) is known to have cardiovascular benefits. Patients on FOS had lower urinary 11-dehydrothromboxane B2 levels regardless of lipid-lowering therapy."

Read More

The improvement of walking abilities and endothelial function after the supervised training treadmill program

"In this prospective study we evaluated the relationship between thromboxane B2 (TXB2), prostacyclin (PGI2) and lactate concentrations, and the improvement of walking abilities and endothelial function in patients with peripheral artery disease (PAD) undergoing a supervised treadmill training program (STTP)."

The Maximal Walking Time (MWT) improved significantly after STTP by 91% (p<0.0001) and PFWT by 97% (P<0.0001).  Also ankle/brachial index (ABI) values improved significantly after STTP in all patient groups and was more pronounced in those with longer MWT at baseline.  FMD values increased by 45% (p<0.0001) after STTP.  Urinary 11-dehydro-thromboxane B2 and 2, 3-dinor-6-keto-PGF1a concentration tend to decrease after STTP and their ratio remained unchanged.  Lactate levels did not change after the treadmill training program.  Hs-CRP and fibrinogen concentration decreased signficantly after STTP only in patients with longer MWT at baseline - fourth quartile".

"STTP in patients with PAD showed signficantly improved walking abilities and endothelialial function."

Read More